GERN Geron Corporation - Common Stock
NASDAQ · Biotechnology · Wyświetl na SEC EDGAR ↗ zamknij Paź 2, 2026 10-K/10-Q Sie 5, 2026GERN Migawka akcji Cena, kapitalizacja rynkowa, P/E, EPS, ROE, zadłużenie/kapitał własny, zakres 52-tygodniowy
GERN Wykres ceny akcji Dzienny OHLCV ze wskaźnikami technicznymi — przesuwaj, powiększaj i dostosowuj widok
Granularność słupków dostosowuje się do wybranego okresu — najedź kursorem na wykres, aby zobaczyć otwarcia/maksima/minima/zamknięcia dla danego słupka.
| Data ex-dywidendy | Podział | Typ |
|---|---|---|
| 22 lipca 2014 | 529-for-500 | Naprzód |
O Geron Corporation - Common Stock Przegląd firmy z Wikipedii
Geron Corporation is a biotechnology company located in Foster City, California which specializes in developing and commercializing therapeutic products for cancer that inhibit telomerase.
Company information
Geron, based in Foster City, California, was founded by gerontologist Mary C. West and Michael D. West, now CEO of AgeX Therapeutics. They secured initial venture capital investments in the company from Kleiner Perkins Caufield & Byers and Venrock. The company was incorporated in 1990 and began doing business in 1992. John A. Scarlett was appointed CEO in 2011.
The company's Scientific and Clinical Advisory Board has included Nobel laureates James Watson, Gunter Blobel, and Carol Greider, and Leonard Hayflick, known for discovering that human cells divide for a limited number of times in vitro (called the Hayflick limit).
In 2017, Geron staff received the highest median pay in California, at $500,250.
Drug candidates
Cancer therapies
Geron Corporation has sponsored human clinical trials of several potential anti-cancer products.
Imetelstat (GRN163L) is a drug that targets telomerase. In studies conducted at Johns Hopkins University, GRN163L was active against both CD138+ and CD138neg cancer stem cells and eliminated the colony forming potential of both by five weeks. Similarly, GRN163L inhibited the in vitro clonogenic growth of CD138neg Multiple Myeloma Cancer Stem Cells isolated from the bone marrow aspirates of patients with multiple myeloma. On November 3, 2014, the FDA removed the full clinical hold on imetelstat and declared the company's clinical development plan as acceptable. In 2014, Geron licensed imetelstat to Janssen Biotech. In 2017, imetelstat was granted fast track status by the FDA for certain patients with myelodysplastic syndrome. In 2018, Janssen Biotech returned the rights to imetelstat to Geron. Imetelstat is currently in two Phase 3 trials: NCT02598661, a study of the drug's ability to reduce the transfusion requirements of patients with myelodysplastic syndrome (MDS), and NCT04576156, an investigation of the drug's effect on the overall survival of patients with myelofibrosis.
A trial of GRNVAC1, a telomerase vaccine being used on patients with prostate cancer was carried out at Duke University. Geron's progress with telomerase vaccines attracted a modest monetary investment in 2005 from Merck.
GRN1005, an LRP-directed conjugate of paclitaxel, was in phase II clinical trials for brain cancer but discontinued based on preliminary results in 2012.
Telomerase activation
In addition to testing drug candidates that exploit cancer cell's dependence on telomerase, Geron is researching the possible applications of activating the enzyme in normal cells to delay cellular senescence. The company is in the early stages of developing a telomerase based treatment for HIV called TAT0002, which is the saponin cycloastragenol in Chinese herb Astragalus propinquus. Geron has granted a license to Telomerase Activation Sciences to sell TA-65, the telomerase activator agent also derived from astragalus. In October 2010 Intertek/AAC Labs, an ISO 17025 internationally recognized lab, found the largest component of TA-65 to be cycloastragenol.
Geron originally investigated telomerase as a means of understanding and modifying human aging. However, Geron has ceased aging research of any kind.
Stem cell therapies
On January 23, 2009, Geron received FDA approval to begin Phase I testing of GRNOPC1 in humans. GRNOPC1 is an embryonic stem cell based drug that is designed to treat specific forms of spinal cord injury through remyelination of damaged axons. This trial does not involve direct use of stem cells however, as GRNOPC1 is composed of oligodendrocyte progenitor cells derived from embryonic stem cell lines. Studies have shown significant restoration of mobility in animals with spinal injuries that received cells.
Geron also has several other embryonic stem cell treatments that are still in the preclinical phase, including GRNCM1, a treatment for heart disease, and GRNIC1, a treatment for diabetes. In tests with diabetic mice, 80% of the mice given GRNIC1 were still alive in 50 days while the entire control group, which was given no treatment, perished.
Geron sold its human stem cell research assets to Asterias in 2013.
GRNOPC1
As of October 2010 and November 2010, one of Geron's most highly publicized trial therapy products has been GRNOPC1, a stem cell therapy designed to heal severe spinal cord injuries. The cells in the GRNOPC1 therapy have been coaxed into becoming early myelinated glial cells, a type of cell that insulates nerve cells. For every GRNOPC1 cell that is injected in the patient, they become six to ten cells in a few months.
In October 2011 updated results on four patients were released. The trial was discontinued in Nov 2011.
In early 2013 BioTime, whose CEO at the time was Geron founder Michael D. West, acquired 400 patents and other intellectual property related to embryonic stem cells from Geron and later went on to restart the trial.
Patent issues
Geron Corporation initially held exclusive rights to three cell types derived from embryonic stem cells, as the result of paying for the research originally conducted by Dr. James Thomson at the University of Wisconsin–Madison. The patents on the other three cell types are owned by the Wisconsin Alumni Research Foundation (WARF). WARF and Geron did not charge academics to study human stem cells but did charge commercial users. In 2001 WARF came under public pressure to widen access to human stem-cell technology, and they launched legal action against Geron Corporation to recover some of the previously sold rights. The two sides agreed that Geron would keep the rights to only three cell types.
In October 2006, a legal challenge was mounted to overturn these patents by The Foundation for Taxpayer and Consumer Rights and the non-profit patent-watchdog Public Patent Foundation. They contended that two of the patents granted to WARF are invalid because they cover a technique published in 1992 for which a patent had already been granted to an Australian researcher. Another part of the challenge came from the molecular biologist Jeanne Loring who stated that University of Wisconsin–Madison stem cell pioneer James Thomson's techniques (currently patents held by WARF) are rendered obvious by a 1990 paper and two textbooks. The outcome of this legal challenge was particularly relevant to the Geron Corporation as it can only license patents that are upheld. The patents were ultimately upheld when the reexamination concluded in 2008.
As an interim measure, on January 23, 2007, WARF relaxed the stem cell patents, allowing industry-sponsored research at academic and non-profit institutions without a license. WARF will allow easier and simpler cost free cell transfers among researchers and would not require a license or agreement from California's taxpayer-funded stem cell research program.
Politics
As a participant in the then-controversial stem cell and cloning area, Geron Corporation was asked to testify about its technology before the U.S. Congress. In 2001, when Congress was attempting to ban all forms of cloning, then Geron CEO Thomas Okarma spoke before Congress to preserve cloning for therapeutic purposes.
Źródło: Wikipedia (Angielski), CC BY-SA 4.0 · Zobacz w Wikipedii ↗
Wyniki 10-letnie Trendy przychodów, zysku netto, marż i EPS
Wycena Wskaźniki P/E, P/S, P/B, EV/EBITDA — czy akcje są drogie, czy tanie?
| Wskaźnik | Trend 5-letni | GERN | średnia z 5 lat | Mediana porównawcza | Werdykt |
|---|---|---|---|---|---|
| P/E | -0.0średnia z 5 lat ≈-8.0 | ≈-8.0 | · | · | |
| P/S | 0.0średnia z 5 lat ≈1359.4 | ≈1359.4 | 8.0 | Niedowartościowany | |
| P/B (MRQ) | 0.0średnia z 5 lat ≈6.2 | ≈6.2 | 2.7 | Niedowartościowany | |
| EV / EBITDA | -0.6średnia z 5 lat ≈-8.4 | ≈-8.4 | · | · | |
| Price / Cash Flow (Cena / Przepływy pieniężne) | -0.0średnia z 5 lat ≈-7.2 | ≈-7.2 | · | · | |
| EV / Revenue (EV / Przychody) | 0.3średnia z 5 lat ≈1370.0 | ≈1370.0 | · | · | |
| Price / Tangible Book (Cena / Wartość księgowa materialna) | 0.0średnia z 5 lat ≈6.2 | ≈6.2 | · | · |
Mediana porównawcza jest obliczana na znormalizowanej podstawie dla każdej metryki i może nie zawsze odpowiadać podstawie TTM/MRQ pokazanej dla tej akcji.
Rentowność Marże brutto, operacyjne i netto; ROE, ROA, ROIC
| Wskaźnik | Trend 5-letni | GERN | średnia z 5 lat | Mediana porównawcza | Werdykt |
|---|---|---|---|---|---|
| ROA | -14.3%średnia z 5 lat ≈-45.5% | ≈-45.5% | -33.0% | Najwyższa półka | |
| ROE | -34.4%średnia z 5 lat ≈-79.6% | ≈-79.6% | -39.4% | Zgodnie z | |
| ROIC | -19.9% | · | -34.7% | Najwyższa półka |
Zdrowie finansowe Dług, płynność, wypłacalność — siła bilansu
| Wskaźnik | Trend 5-letni | GERN | średnia z 5 lat | Mediana porównawcza | Werdykt |
|---|---|---|---|---|---|
| Dług / Kapitał Własny (MRQ) | 0.5średnia z 5 lat ≈0.5 | ≈0.5 | · | · | |
| Wskaźnik bieżący (MRQ) | 6.9średnia z 5 lat ≈4.0 | ≈4.0 | 8.9 | Niska płynność | |
| Quick Ratio (Wskaźnik Szybkości) | 1.0średnia z 5 lat ≈0.9 | ≈0.9 | 7.6 | Niska płynność | |
| Dług długoterminowy / Kapitał własny (MRQ) | 0.5średnia z 5 lat ≈0.4 | ≈0.4 | · | · |
Rozwój Wzrost przychodów, EPS i zysku netto: r/r, CAGR 3-letni, CAGR 5-letni
| Wskaźnik | Trend 5-letni | GERN | średnia z 5 lat | Mediana porównawcza | Werdykt |
|---|---|---|---|---|---|
| Revenue YoY (Przychody R/R) | -60.2%średnia z 5 lat ≈111.0% | ≈111.0% | · | · | |
| Revenue CAGR 3Y (Przychody CAGR 3L) | -2.1% | · | · | · |
Efektywność kapitałowa Rotacja aktywów, rotacja zapasów, rotacja należności
| Wskaźnik | Trend 5-letni | GERN | średnia z 5 lat | Mediana porównawcza | Werdykt |
|---|---|---|---|---|---|
| Revenue / Employee (Przychody / pracownika) | ≈$918.60 | · | · | · |
wartość · ≈ średnia z 5 lat · mediana branżowa · werdykt względem mediany
Historia zysków EPS faktyczny vs szacowany, zaskoczenie %, wskaźnik trafień, data następnych wyników
| Okres | Raport | EPS Actual | EPS Szacowany | Niespodzianka |
|---|---|---|---|---|
| 30 czerwca 2026 | Sie 6, 2026 | $-0.02 | $-0.01 | — |
| 31 marca 2026 | $-0.01 | $-0.02 | 52.6% | |
| 31 grudnia 2025 | $-0.02 | $-0.03 | 38.1% | |
| 30 września 2025 | $-0.03 | $-0.03 | 11.0% | |
| 30 czerwca 2025 | $-0.02 | $-0.03 | 35.7% | |
| 31 marca 2025 | $-0.03 | $-0.04 | 22.3% |
Pełne podstawowe wskaźniki Wszystkie wskaźniki roczne — rachunek zysków i strat, bilans, przepływy pieniężne
Rachunek zysków i strat
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | · | · | $237.0K | $596.0K | $1M | $253.0K | $460.0K | $1M | $1M | $6M | $36M | $1M | |
| SG&A Expense | $159M | $146M | $69M | $44M | $30M | $26M | $21M | $19M | $19M | $19M | $18M | $17M | |
| Operating Expenses | $252M | $251M | $194M | $139M | $115M | $77M | $73M | $32M | $30M | $37M | $37M | $37M | |
| Operating Income | $-69M | $-174M | $-194M | $-139M | $-114M | $-77M | $-73M | $-31M | $-29M | $-31M | $-559.0K | $-36M | |
| Interest Expense | · | $19M | $8M | $7M | $4M | $760.0K | · | · | · | · | · | · | |
| Interest Income | $18M | $20M | $18M | $3M | $527.0K | $2M | $4M | $3M | · | · | · | · | |
| Other Non-op | $-375.0K | $-236.0K | $-23.0K | $1M | $1M | $168.0K | $-69.0K | $-114.0K | · | · | · | · | |
| Pretax Income | $-83M | $-175M | $-182M | $-142M | · | · | · | · | · | · | · | · | |
| Income Tax | $75.0K | $449.0K | $22.0K | · | · | · | · | · | · | · | · | · | |
| Net Income | $-84M | $-175M | $-184M | $-142M | $-116M | $-76M | $-69M | $-27M | $-28M | $-30M | $46.0K | $-36M | |
| EPS (Basic) | $-0.13 | $-0.27 | $-0.32 | $-0.37 | $-0.35 | $-0.28 | · | · | $-0.18 | $-0.19 | $0.00 | $-0.23 | |
| EPS (Diluted) | $-0.13 | $-0.27 | $-0.32 | $-0.37 | $-0.35 | $-0.28 | · | · | $-0.18 | $-0.19 | $0.00 | $-0.23 | |
| Shares (Basic) | 666,662,989 | 646,033,247 | 570,645,405 | 380,784,846 | 327,631,814 | 271,460,265 | · | · | 159,224,986 | 159,045,644 | 158,036,162 | 153,540,341 | |
| Shares (Diluted) | 666,662,989 | 646,033,247 | 570,645,405 | 380,784,846 | 327,631,814 | 271,460,265 | · | · | 159,224,986 | 159,045,644 | 162,663,894 | 153,540,341 | |
| EBITDA | $-69M | $-174M | $-194M | $-139M | $-114M | $-77M | $-73M | $-31M | $-29M | $-31M | $-559.0K | $-36M |
Bilans
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $78M | $79M | $70M | $57M | $35M | $10M | $14M | $11M | $16M | $13M | $21M | $43M | |
| Short-term Investments | · | · | · | · | · | · | · | · | $78M | $102M | $93M | $109M | |
| Receivables | $37M | $36M | · | · | · | · | · | · | · | · | · | · | |
| Inventory | $117M | $39M | · | · | · | · | · | · | · | · | · | · | |
| Prepaid Expense | $5M | $5M | $5M | $4M | $1M | $2M | $1M | $1M | $580.0K | $524.0K | $647.0K | $736.0K | |
| Current Assets | $520M | $491M | $341M | $180M | $187M | $200M | $142M | $166M | $96M | $116M | $116M | $153M | |
| PP&E (Net) | $884.0K | $1M | $1M | $793.0K | $650.0K | $658.0K | $408.0K | $59.0K | $102.0K | $183.0K | $207.0K | $173.0K | |
| PP&E (Gross) | $3M | $3M | $2M | $2M | $1M | $1M | $1M | $838.0K | $822.0K | $1M | $1M | $1M | |
| Accum. Depreciation | $2M | $2M | $1M | $896.0K | $650.0K | $613.0K | $843.0K | $779.0K | $720.0K | $1M | $1M | $1M | |
| Other Non-current Assets | · | · | · | · | · | · | · | $585.0K | · | · | · | · | |
| Total Assets | $571M | $594M | $394M | $191M | $226M | $271M | $166M | $185M | $110M | $130M | $149M | $173M | |
| Accounts Payable | $11M | $9M | $6M | $10M | $7M | $7M | $1M | $982.0K | $503.0K | $225.0K | $160.0K | $1M | |
| Accrued Liabilities | $51M | $36M | $40M | $33M | $30M | $15M | $8M | $1M | $926.0K | $1M | $1M | $2M | |
| Current Liabilities | $112M | $88M | $108M | $77M | $46M | $31M | $28M | $8M | $7M | $8M | $7M | $42M | |
| Capital Leases | $1M | $2M | $3M | $4M | $4M | $5M | $2M | · | · | · | · | · | |
| Total Liabilities | $345M | $313M | $146M | $111M | $100M | $60M | $30M | · | · | · | · | · | |
| Long-term Debt | · | · | $82M | $51M | · | · | · | · | · | · | · | · | |
| Total Debt | $120M | $118M | $82M | $51M | $50M | $24M | · | · | · | · | · | · | |
| Common Stock | $640.0K | $606.0K | $545.0K | $390.0K | $324.0K | $310.0K | $200.0K | $186.0K | $160.0K | $159.0K | $159.0K | $157.0K | |
| Retained Earnings | $-1.86B | $-1.77B | $-1.60B | $-1.41B | $-1.27B | $-1.16B | $-1.08B | $-1.01B | $-986M | $-958M | $-928M | $-928M | |
| AOCI | $269.0K | $261.0K | $185.0K | $-219.0K | $-173.0K | $78.0K | $132.0K | $-183.0K | $-207.0K | $-53.0K | $-213.0K | $-84.0K | |
| Stockholders' Equity | $226M | $280M | $248M | $80M | $126M | $211M | $135M | $178M | $104M | $122M | $142M | $131M | |
| Liabilities + Equity | $571M | $594M | $394M | $191M | $226M | $271M | $166M | $185M | $110M | $130M | $149M | $173M | |
| Shares Outstanding | 639,856 | 606,388,000 | 544,912,215 | 390,262,524 | 323,731,591 | 310,566,853 | 199,814,581 | 186,392,682 | 159,877,239 | 159,158,636 | 158,781,359 | 157,429,871 |
Przepływy pieniężne
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $474.0K | $546.0K | $442.0K | $288.0K | $215.0K | $158.0K | $64.0K | · | · | · | · | · | |
| Stock-based Comp | $27M | $31M | $19M | $8M | $8M | $7M | $6M | $6M | $8M | $8M | $8M | $8M | |
| Restructuring | $17M | $0 | $0 | · | · | · | · | · | · | · | $1M | · | |
| Operating Cash Flow | $-111M | $-219M | $-168M | $-127M | $-96M | $-67M | $-44M | $-21M | $-21M | $-18M | $-24M | $9M | |
| CapEx | · | $680.0K | $830.0K | $431.0K | $207.0K | $401.0K | $413.0K | $16.0K | · | $57.0K | $90.0K | $131.0K | |
| Investing Cash Flow | $107M | $-106M | $-180M | $62M | $72M | $-105M | $27M | $-78M | $23M | $9M | $73.0K | · | |
| Debt Issued | $0 | $121M | $30M | · | $25M | $24M | · | · | · | · | · | · | |
| Net Debt Issued | $0 | $35M | $30M | · | $25M | $24M | · | · | · | · | · | · | |
| Stock Issued | · | · | · | · | $20M | $4M | $19M | $86M | $1M | $1M | $3M | $98M | |
| Net Stock Activity | · | · | · | · | $20M | $4M | $19M | $86M | $1M | $1M | $3M | $98M | |
| Dividends Paid | · | · | · | · | · | · | · | · | · | · | $0 | $0 | |
| Financing Cash Flow | $2M | $334M | $362M | $87M | $49M | $168M | $19M | $93M | $1M | $1M | $3M | · | |
| Net Change in Cash | $-1M | $10M | $14M | $22M | $25M | · | · | · | $4M | $-8M | $-22M | · | |
| Free Cash Flow | · | $-219M | $-169M | $-128M | $-96M | $-67M | $-44M | $-21M | · | $-18M | $-24M | $9M | |
| Levered FCF | · | $-238M | · | · | · | · | · | · | · | · | · | · |
Rentowność
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | · | · | -81832.9% | -23246.6% | -8183.7% | -30400.4% | -15762.0% | -2914.9% | -2746.9% | -497.3% | -1.5% | · | |
| Net Margin | · | · | -77690.7% | -23808.9% | -8335.4% | -29888.1% | -14901.7% | -2534.4% | -2621.2% | -479.3% | 0.13% | · | |
| EBITDA Margin | · | · | -81832.9% | -23246.6% | -8183.7% | -30400.4% | -15762.0% | -2914.9% | -2746.9% | -497.3% | -1.5% | · | |
| ROA | -14.3% | -35.3% | -63.0% | -68.1% | -46.8% | -34.7% | -39.1% | -18.3% | -23.2% | -21.2% | 0.03% | -29.7% | |
| ROE | -34.4% | -61.0% | -68.4% | -150.8% | -83.5% | -34.1% | -47.7% | -15.0% | -24.7% | -22.3% | 0.03% | -37.5% | |
| ROIC | -19.9% | -43.7% | · | · | · | · | · | · | · | · | · | · |
Płynność i wypłacalność
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.7 | 5.6 | 3.2 | 2.4 | 4.1 | 6.5 | 5.0 | 22.0 | 14.7 | 14.8 | 17.5 | 3.7 | |
| Quick Ratio | 1.0 | 1.3 | 0.6 | 0.7 | 0.8 | 0.3 | 0.5 | 1.4 | 14.5 | 14.6 | 17.1 | 3.6 | |
| Debt / Equity | 0.5 | 0.4 | 0.3 | 0.6 | 0.4 | 0.1 | · | · | · | · | · | · | |
| LT Debt / Equity | 0.5 | 0.4 | 0.1 | 0.4 | 0.4 | 0.1 | · | · | · | · | · | · | |
| Interest Coverage | · | -9.4 | -23.3 | -20.1 | -30.5 | -101.2 | · | · | · | · | · | · |
Efektywność
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | · | · | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.2 | · |
Na akcję
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $0.35 | $0.46 | $0.46 | $0.20 | $0.39 | $0.68 | $0.68 | $0.95 | $0.65 | $0.77 | $0.90 | $0.83 | |
| Revenue / Share | · | · | $0.00 | $0.00 | · | · | · | · | $0.01 | $0.04 | $0.22 | · | |
| Cash Flow / Share | $-0.17 | $-0.34 | $-0.29 | $-0.33 | · | · | · | · | $-0.13 | $-0.12 | $-0.15 | · | |
| Cash / Share | $0.12 | $0.13 | $0.13 | $0.15 | $0.11 | $0.03 | $0.07 | $0.06 | $0.10 | $0.08 | $0.13 | $0.27 | |
| EPS (TTM) | $-0.13 | $-0.27 | $-0.32 | $-0.37 | $-0.35 | $-0.28 | · | · | $-0.18 | $-0.19 | $0.00 | $-0.23 |
Stopy Wzrostu
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | · | · | -60.2% | -57.2% | 450.6% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | · | · | -2.1% | · | · | · | · | · | · | · | · | · |
Wycena (TTM)
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $164M | $30M | $237.0K | $596.0K | $1M | $253.0K | $460.0K | $1M | $1M | $6M | $36M | $1M | |
| Net Income TTM | $-84M | $-175M | $-184M | $-142M | $-116M | $-76M | $-69M | $-27M | $-28M | $-30M | $46.0K | $-36M | |
| Market Cap | $845M | $2.15B | $1.15B | $944M | $395M | $494M | $272M | $186M | $288M | $329M | $769M | $512M | |
| Enterprise Value | $887M | $2.19B | $1.16B | $939M | $410M | $508M | · | · | · | · | · | · | |
| P/E | -10.2 | -13.1 | -6.6 | -6.5 | -3.5 | -5.7 | · | · | -10.0 | -10.9 | · | -14.1 | |
| P/S | 5.1 | 72.5 | 4851.3 | 1584.6 | 283.5 | 1951.8 | 590.8 | 174.9 | 270.2 | 53.5 | 21.1 | 443.8 | |
| P/B | 3.7 | 7.7 | 4.6 | 11.8 | 3.1 | 2.3 | 2.0 | 1.0 | 2.8 | 2.7 | 5.4 | 3.9 | |
| P / Tangible Book | 3.7 | 7.7 | 4.6 | 11.8 | 3.1 | 2.3 | · | · | · | · | · | · | |
| P / Cash Flow | -7.6 | -9.8 | -6.9 | -7.4 | -4.1 | -7.4 | -6.2 | -8.9 | -14.0 | -17.9 | -31.8 | 54.7 | |
| P / FCF | · | -9.8 | -6.8 | -7.4 | -4.1 | -7.4 | -6.1 | -8.9 | · | -17.9 | -31.6 | 55.5 | |
| EV / EBITDA | -12.9 | -12.6 | -6.0 | -6.8 | -3.6 | -6.6 | · | · | · | · | · | · | |
| EV / FCF | · | -10.0 | -6.9 | -7.3 | -4.3 | -7.6 | · | · | · | · | · | · | |
| EV / Revenue | 5.4 | 73.8 | 4901.6 | 1575.1 | 294.3 | 2007.6 | · | · | · | · | · | · | |
| Dividend Yield | · | · | · | · | · | · | · | · | · | · | 0.00% | 0.00% | |
| Earnings Yield | -9.8% | -7.6% | -15.2% | -15.3% | -28.7% | -17.6% | · | · | -10.0% | -9.2% | 0.00% | -7.1% | |
| Payout Ratio | · | · | · | · | · | · | · | · | · | · | 0.00% | 0.00% | |
| Annual Payout | · | · | · | · | · | · | · | · | · | · | $0 | $0 |
Rachunek zysków i strat
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $57M | $52M | · | $47M | $49M | $40M | · | $28M | $882.0K | $304.0K | $164.0K | $29.0K | $21.0K | $297.0K | $73.0K | $123.0K | |
| SG&A Expense | $39M | $35M | $42M | $39M | $39M | $40M | $43M | $36M | $39M | $27M | $18M | $16M | $13M | $16M | $7M | $7M | |
| Operating Expenses | $70M | $52M | $74M | $61M | $61M | $56M | $68M | $56M | $70M | $56M | $48M | $52M | $40M | $40M | $28M | $29M | |
| Operating Income | $-12M | $158.0K | $-26M | $-14M | $-12M | $-17M | $-20M | $-28M | $-69M | $-56M | $-48M | $-52M | $-40M | $-40M | $-28M | $-29M | |
| Interest Expense | · | · | · | · | · | · | · | $3M | $3M | $3M | $2M | $2M | $2M | $2M | $2M | $1M | |
| Interest Income | $3M | $3M | $4M | $4M | $5M | $5M | $5M | $5M | $5M | $4M | $5M | $5M | $4M | $852.0K | $330.0K | $112.0K | |
| Other Non-op | $-9.0K | $-74.0K | $-70.0K | $-161.0K | $-61.0K | $-83.0K | $-48.0K | $-63.0K | $-63.0K | $-62.0K | $-92.0K | $-11.0K | $39.0K | $-138.0K | $1M | $-56.0K | |
| Net Income | $-17M | $-4M | $-29M | $-18M | $-16M | $-20M | $-25M | $-26M | $-67M | $-55M | $-45M | $-49M | $-38M | $-41M | $-28M | $-30M | |
| EPS (Basic) | $-0.02 | $-0.01 | $-0.05 | $-0.03 | $-0.02 | $-0.03 | $-0.04 | $-0.04 | $-0.10 | $-0.09 | $-0.08 | $-0.09 | $-0.07 | $-0.10 | $-0.07 | $-0.09 | |
| EPS (Diluted) | $-0.02 | $-0.01 | $-0.05 | $-0.03 | $-0.02 | $-0.03 | $-0.04 | $-0.04 | $-0.10 | $-0.09 | $-0.08 | $-0.09 | $-0.07 | $-0.10 | $-0.07 | $-0.09 | |
| Shares (Basic) | 670,696 | 669,375 | · | 667,101,756 | 666,170 | 665,905 | · | 662,158,182 | 653,904,978 | 603,493,451 | 579,508,305 | 547,280,946 | 544,459,004 | 405,237,474 | 403,868,713 | 332,066,889 | |
| Shares (Diluted) | 670,696 | 669,375 | · | 667,101,756 | 666,170 | 665,905 | · | 662,158,182 | 653,904,978 | 603,493,451 | 579,508,305 | 547,280,946 | 544,459,004 | 405,237,474 | 403,868,713 | 332,066,889 | |
| EBITDA | $-12M | $158.0K | · | $-14M | $-12M | $-17M | · | $-28M | $-69M | $-56M | $-48M | $-52M | $-40M | $-40M | $-28M | $-29M |
Bilans
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $63M | $69M | $78M | $78M | $78M | $84M | $79M | $60M | $117M | $190M | $31M | $57M | $113M | $61M | $76M | $31M | |
| Receivables | $52M | $42M | $37M | $35M | $37M | $31M | $36M | $28M | $874.0K | · | · | · | · | · | · | · | |
| Inventory | $124M | $133M | $117M | $95M | $69M | $56M | $39M | $20M | $774.0K | · | · | · | · | · | · | · | |
| Prepaid Expense | $6M | $7M | $5M | $7M | $7M | $7M | $5M | $6M | $6M | $6M | $6M | $4M | $4M | $5M | $3M | $4M | |
| Current Assets | $486M | $499M | $520M | $522M | $506M | $496M | $491M | $398M | $373M | $452M | $335M | $377M | $387M | $222M | $227M | $176M | |
| PP&E (Net) | $1M | $1M | $884.0K | $973.0K | $1M | $1M | $1M | $2M | $2M | $2M | $1M | $1M | $1M | $733.0K | $641.0K | $643.0K | |
| PP&E (Gross) | · | · | $3M | · | · | · | $3M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $2M | · | · | · | $2M | · | · | · | · | · | · | · | · | · | |
| Total Assets | $519M | $534M | $571M | $567M | $555M | $562M | $594M | $445M | $449M | $482M | $413M | $415M | $425M | $233M | $238M | $198M | |
| Accounts Payable | $9M | $13M | $11M | $11M | $8M | $8M | $9M | $14M | $6M | $10M | $14M | $8M | $3M | $8M | $5M | $6M | |
| Accrued Liabilities | $31M | $31M | $51M | $40M | $26M | $29M | $36M | $36M | $39M | $34M | $42M | $45M | $35M | $53M | $31M | $36M | |
| Current Liabilities | $70M | $74M | $112M | $88M | $64M | $63M | $88M | $138M | $104M | $123M | $89M | $73M | $44M | $83M | $47M | $47M | |
| Capital Leases | $1M | $1M | $1M | $2M | $2M | $2M | $2M | $2M | $3M | $3M | $3M | $3M | $4M | $4M | $4M | $4M | |
| Total Liabilities | $300M | $305M | $345M | · | · | · | $313M | · | · | · | · | · | · | · | · | · | |
| Long-term Debt | · | · | · | · | · | · | · | $84M | $83M | $83M | $52M | $52M | $51M | $51M | $50M | · | |
| Total Debt | $120M | $120M | · | $119M | $119M | $119M | · | $84M | $83M | $83M | $52M | $52M | $51M | $51M | $50M | $50M | |
| Common Stock | $642.0K | $641.0K | $640.0K | $638.0K | $638.0K | $637.0K | $606.0K | $603.0K | $601.0K | $591.0K | $542.0K | $522.0K | $509.0K | $382.0K | $378.0K | $324.0K | |
| Retained Earnings | $-1.88B | $-1.86B | $-1.86B | $-1.83B | $-1.81B | $-1.79B | $-1.77B | $-1.75B | $-1.72B | $-1.65B | $-1.55B | $-1.50B | $-1.45B | $-1.37B | $-1.33B | $-1.30B | |
| AOCI | $-339.0K | $-191.0K | $269.0K | $408.0K | $117.0K | $304.0K | $261.0K | $1M | $-537.0K | $-273.0K | $-950.0K | $-945.0K | $-160.0K | $-620.0K | $-782.0K | $-711.0K | |
| Stockholders' Equity | $219M | $229M | $226M | $249M | $260M | $268M | $280M | $292M | $307M | $345M | $291M | $298M | $326M | $108M | $142M | $97M | |
| Liabilities + Equity | $519M | $534M | $571M | $567M | $555M | $562M | $594M | $445M | $449M | $482M | $413M | $415M | $425M | $233M | $238M | $198M | |
| Shares Outstanding | 642,470 | 641,033,000 | 639,856,222 | 638,355,275 | 637,849,739 | 636,917,758 | 606,387,666 | 603,102,073 | 601,048,108 | 591,163,808 | 542,479,666 | 521,942,104 | 508,731,846 | 381,214,326 | 377,664,759 | 323,736,875 |
Przepływy pieniężne
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $136.0K | $134.0K | $87.0K | $128.0K | $128.0K | $131.0K | $142.0K | $31.0K | $262.0K | $111.0K | $108.0K | $121.0K | $99.0K | $79.0K | $72.0K | $57.0K | |
| Stock-based Comp | $5M | $5M | $6M | $7M | $7M | $7M | $7M | $7M | $13M | $5M | $7M | $4M | $3M | $2M | $2M | $2M | |
| Restructuring | $-157.0K | $-394.0K | · | · | $0 | $0 | · | · | · | · | · | · | · | · | · | · | |
| Operating Cash Flow | $-16M | $-63M | $-22M | $-14M | $-27M | $-48M | $-44M | $-59M | $-53M | $-62M | $-51M | $-30M | $-46M | $-30M | $-29M | $-34M | |
| CapEx | · | · | · | · | · | · | · | $0 | $206.0K | $615.0K | $192.0K | $202.0K | $372.0K | $171.0K | $70.0K | $50.0K | |
| Investing Cash Flow | $8M | $52M | $21M | $13M | $20M | $52M | $-104M | $-554.0K | $-36M | $34M | $-5M | $-44M | $-179M | $10M | $3M | $30M | |
| Financing Cash Flow | $1M | $2M | $378.0K | $542.0K | $1M | $256.0K | $166M | $4M | $17M | $148M | $29M | $18M | $281M | $5M | · | · | |
| Net Change in Cash | $-6M | $-9M | $-553.0K | $389.0K | $-6M | $5M | $19M | $-56M | $-73M | $120M | $-26M | $-56M | $56M | $-15M | $45M | $-4M | |
| Free Cash Flow | · | · | · | · | · | · | · | · | · | $-63M | · | · | $-47M | · | · | $-34M |
Rentowność
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -21.7% | 0.30% | · | -29.4% | -25.4% | -42.2% | · | -99.8% | -7860.9% | -18465.1% | -29031.7% | -179141.4% | -190914.3% | -13450.5% | -38323.3% | -23313.0% | |
| Net Margin | -29.0% | -7.0% | · | -39.0% | -33.4% | -50.1% | · | -93.5% | -7639.8% | -18220.4% | -27320.1% | -169748.3% | -181533.3% | -13821.9% | -38516.4% | -24469.9% | |
| EBITDA Margin | -21.7% | 0.30% | · | -29.4% | -25.4% | -42.2% | · | -99.8% | -7860.9% | -18465.1% | -29031.7% | -179141.4% | -190914.3% | -13450.5% | -38323.3% | -23313.0% | |
| ROA | -3.1% | -0.66% | · | -3.6% | -3.3% | -3.8% | · | -6.2% | -15.6% | -12.2% | -13.9% | -15.1% | -12.2% | -17.8% | -11.5% | -13.2% | |
| ROE | -7.0% | -1.5% | · | -6.8% | -5.8% | -6.5% | · | -9.1% | -22.3% | -16.5% | -22.5% | -22.4% | -18.0% | -31.6% | -17.7% | -20.2% |
Płynność i wypłacalność
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 6.9 | 6.8 | · | 6.0 | 7.9 | 7.9 | · | 2.9 | 3.6 | 3.7 | 3.7 | 5.2 | 8.8 | 2.7 | 4.9 | 3.8 | |
| Quick Ratio | 1.6 | 1.5 | · | 1.3 | 1.8 | 1.8 | · | 0.6 | 1.1 | 1.5 | 0.3 | 0.8 | 2.6 | 0.7 | 1.6 | 0.7 | |
| Debt / Equity | 0.5 | 0.5 | · | 0.5 | 0.5 | 0.4 | · | 0.3 | 0.3 | 0.2 | 0.2 | 0.2 | 0.2 | 0.5 | 0.4 | 0.5 | |
| LT Debt / Equity | 0.5 | 0.5 | · | 0.5 | 0.5 | 0.4 | · | 0.0 | 0.1 | 0.0 | 0.1 | 0.1 | 0.2 | 0.3 | 0.3 | 0.5 | |
| Interest Coverage | · | · | · | · | · | · | · | -9.3 | -20.9 | -16.4 | -23.0 | -25.9 | -20.9 | -22.0 | -17.7 | -19.4 |
Efektywność
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Receivables Turnover | 1.3 | 1.4 | · | 1.5 | 2.6 | 2.5 | · | 2.0 | 2.0 | · | · | · | · | · | · | · |
Na akcję
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $340.27 | $0.36 | · | $0.39 | $0.41 | $0.42 | · | $0.48 | $0.51 | $0.58 | $0.54 | $0.57 | $0.64 | $0.28 | $0.38 | $0.30 | |
| Revenue / Share | $85.70 | $77.44 | · | $0.07 | $0.07 | $0.06 | · | $0.04 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | · | |
| Cash Flow / Share | · | $-93.98 | · | · | · | $-0.07 | · | · | · | $-0.10 | · | · | $-0.09 | · | · | · | |
| Cash / Share | $97.50 | $0.11 | · | $0.12 | $0.12 | $0.13 | · | $0.10 | $0.19 | $0.32 | $0.06 | $0.11 | $0.22 | $0.16 | $0.20 | $0.10 | |
| EPS (TTM) | $-0.11 | $-0.11 | · | $-0.12 | $-0.13 | $-0.21 | · | $-0.31 | $-0.35 | $-0.34 | $-0.35 | $-0.37 | $-0.35 | $-0.35 | $-0.33 | $-0.35 |
Wycena (TTM)
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | · | · | · | · | · | · | · | · | · | · | · | · | · | $2M | $1M | $1M | |
| Net Income TTM | $-68M | $-67M | · | $-80M | $-88M | $-139M | · | $-201M | $-220M | $-201M | $-175M | $-171M | $-150M | $-131M | $-117M | $-118M | |
| Market Cap | $822.4K | $955M | · | $875M | $899M | $1.01B | · | $2.74B | $2.55B | $1.95B | $1.15B | $1.68B | $1.10B | $892M | $585M | $440M | |
| Enterprise Value | $58M | $1.01B | · | $916M | $941M | $1.05B | · | $2.76B | $2.51B | $1.84B | $1.17B | $1.67B | $1.04B | $882M | $560M | $459M | |
| P/E | -11.6 | -13.5 | · | -11.4 | -10.8 | -7.6 | · | -14.6 | -12.1 | -9.7 | -6.1 | -8.7 | -6.2 | -6.7 | -4.7 | -3.9 | |
| P/S | · | · | · | · | · | · | · | · | · | · | · | · | · | 581.9 | 435.2 | 319.3 | |
| P/B | 0.0 | 4.2 | · | 3.5 | 3.5 | 3.8 | · | 9.4 | 8.3 | 5.7 | 4.0 | 5.6 | 3.4 | 8.2 | 4.1 | 4.5 | |
| P / Tangible Book | 0.0 | 4.2 | · | 3.5 | 3.5 | 3.8 | · | 9.4 | 8.3 | 5.7 | 4.0 | 5.6 | 3.4 | 8.2 | 4.1 | 4.5 | |
| P / Cash Flow | · | -15.2 | · | · | · | -21.1 | · | · | · | -31.3 | · | · | -23.8 | · | · | -13.0 | |
| EV / Revenue | · | · | · | · | · | · | · | · | · | · | · | · | · | 575.1 | 416.2 | 332.9 | |
| Earnings Yield | -8.6% | -7.4% | · | -8.8% | -9.2% | -13.2% | · | -6.8% | -8.2% | -10.3% | -16.5% | -11.5% | -16.1% | -15.0% | -21.3% | -25.7% |
Najnowszy okres po lewej · wartości null pokazane jako ·
Sprawozdania finansowe Rachunek zysków i strat, bilans, przepływy pieniężne — roczne, ostatnie 5 lat
| Wskaźnik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Przychody | · | · | $237.0K | $596.0K | $1M |
| Marża Operacyjna % | · | · | -81832.9% | -23246.6% | -8183.7% |
| Zysk netto | $-84M | $-175M | $-184M | $-142M | $-116M |
| Rozwodniony EPS | $-0.13 | $-0.27 | $-0.32 | $-0.37 | $-0.35 |
| Wskaźnik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Dług / Kapitał Własny | 0.5 | 0.4 | 0.3 | 0.6 | 0.4 |
| Wskaźnik bieżący | 4.7 | 5.6 | 3.2 | 2.4 | 4.1 |
| Wskaźnik Szybkości | 1.0 | 1.3 | 0.6 | 0.7 | 0.8 |
| Wskaźnik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Wolny przepływ pieniężny | · | $-219M | $-169M | $-128M | $-96M |
Właściciele instytucjonalni (13F) 275 emitentów · $662.3M łącznie · Na dzień 30 czerwca 2026
Instytucje, które zgłaszają posiadanie tych akcji w swoich kwartalnych zgłoszeniach SEC Form 13F. Tylko pozycje długie; pojedynczy zgłaszający może pojawić się dwukrotnie dla oddzielnych transz opcji. Duże przeciwstawne pozycje put/call zazwyczaj odzwierciedlają działalność market-makingową lub zabezpieczone zapasy, a nie przekonanie kierunkowe.
| Nowe pozycje | Zamknięte pozycje | Zwiększone | Zmniejszony | Zmiana liczby akcji netto |
|---|---|---|---|---|
| 37 (0 vs poprzedni kw.) | 29 (-7 vs poprzedni kw.) | 94 (+1 vs poprzedni kw.) | 65 (+6 vs poprzedni kw.) | -21.3M |
Porównano z Q1 2026. Zgłoszenia SEC Form 13F są wymagane w ciągu 45 dni od końca kwartału plus krótki bufor dla spóźnionych zgłoszeń — kwartały mieszczące się jeszcze w tym terminie są pomijane na rzecz ostatniej w pełni zgłoszonej pary.
| Instytucja | Wartość | Akcje | % z śledzonych 13F | Typ |
|---|---|---|---|---|
| BlackRock, Inc. | $62 867 932 | 49 115 571 | 9,49% | Akcje |
| RA CAPITAL MANAGEMENT, L.P. | $54 796 481 | 42 809 751 | 8,27% | Akcje |
| Soleus Capital Management, L.P. | $54 795 084 | 42 808 659 | 8,27% | Akcje |
| VANGUARD GROUP INC | $47 072 479 | 35 660 969 | 7,11% | Akcje |
| STATE STREET CORP | $45 896 539 | 35 856 671 | 6,93% | Akcje |
| CITADEL ADVISORS LLC | $37 169 828 | 29 038 928 | 5,61% | Akcje |
| VANGUARD CAPITAL MANAGEMENT LLC | $34 880 275 | 27 250 215 | 5,27% | Akcje |
| Clearbridge Investments, LLC | $25 150 531 | 19 648 853 | 3,80% | Akcje |
| Eversept Partners, LP | $23 958 300 | 18 717 422 | 3,62% | Akcje |
| GOLDMAN SACHS GROUP INC | $21 290 712 | 16 633 368 | 3,21% | Akcje |
| GEODE CAPITAL MANAGEMENT, LLC | $18 635 455 | 14 555 954 | 2,81% | Akcje |
| MORGAN STANLEY | $16 570 152 | 12 945 431 | 2,50% | Akcje |
| Nantahala Capital Management, LLC | $15 648 000 | 12 225 000 | 2,36% | Akcje |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $13 840 125 | 10 812 598 | 2,09% | Akcje |
| Vivo Capital, LLC | $11 099 900 | 8 671 797 | 1,68% | Akcje |
| MILLENNIUM MANAGEMENT LLC | $10 383 702 | 8 112 267 | 1,57% | Akcje |
| Kynam Capital Management, LP | $8 750 487 | 6 836 318 | 1,32% | Akcje |
| Candriam S.C.A. | $7 147 270 | 5 589 182 | 1,08% | Akcje |
| FMR LLC | $7 043 593 | 5 502 807 | 1,06% | Akcje |
| Pale Fire Capital SE | $6 793 221 | 5 307 204 | 1,03% | Akcje |
| NORTHERN TRUST CORP | $6 441 232 | 5 032 212 | 0,97% | Akcje |
| UBS Group AG | $6 267 002 | 4 896 096 | 0,95% | Akcje |
| RENAISSANCE TECHNOLOGIES LLC | $5 861 120 | 4 579 000 | 0,88% | Akcje |
| SEGALL BRYANT & HAMILL, LLC | $5 741 509 | 4 485 554 | 0,87% | Akcje |
| TWO SIGMA INVESTMENTS, LP | $5 514 257 | 4 308 013 | 0,83% | Akcje |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $5 484 367 | 4 284 662 | 0,83% | Akcje |
| TORONTO DOMINION BANK | $5 420 800 | 4 235 000 | 0,82% | Akcje |
| Point72 Asset Management, L.P. | $5 177 857 | 4 045 201 | 0,78% | Akcje |
| VANGUARD FIDUCIARY TRUST CO | $5 073 361 | 3 963 563 | 0,77% | Akcje |
| BANK OF AMERICA CORP /DE/ | $4 523 820 | 3 534 234 | 0,68% | Akcje |
| DEUTSCHE BANK AG\ | $4 403 170 | 3 439 976 | 0,66% | Akcje |
| Qube Research & Technologies Ltd | $4 302 828 | 3 361 584 | 0,65% | Akcje |
| PANAGORA ASSET MANAGEMENT INC | $3 762 520 | 2 939 469 | 0,57% | Akcje |
| JANUS HENDERSON GROUP PLC | $3 303 915 | 2 218 196 | 0,50% | Akcje |
| ExodusPoint Capital Management, LP | $3 233 466 | 2 526 145 | 0,49% | Akcje |
| BNP PARIBAS FINANCIAL MARKETS | $3 093 044 | 2 416 441 | 0,47% | Akcje |
| EDMOND DE ROTHSCHILD HOLDING S.A. | $2 982 400 | 2 330 000 | 0,45% | Akcje |
| NAN FUNG TRINITY (HK) LTD | $2 846 144 | 2 223 550 | 0,43% | Akcje |
| Bank of New York Mellon Corp | $2 071 354 | 1 618 246 | 0,31% | Akcje |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $1 980 466 | 1 547 239 | 0,30% | Akcje |
| Nuveen, LLC | $1 979 489 | 1 546 476 | 0,30% | Akcje |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $1 893 811 | 1 271 014 | 0,29% | Akcje |
| World Investment Advisors | $1 540 331 | 1 033 779 | 0,23% | Akcje |
| MOORE CAPITAL MANAGEMENT, LP | $1 525 684 | 1 191 941 | 0,23% | Akcje |
| Invesco Ltd. | $1 504 266 | 1 175 208 | 0,23% | Akcje |
| Kodai Capital Management LP | $1 420 015 | 893 091 | 0,21% | Akcje |
| Seven Fleet Capital Management LP | $1 353 252 | 1 057 228 | 0,20% | Akcje |
| Virtus Investment Advisers, LLC | $1 294 337 | 1 011 201 | 0,20% | Akcje |
| Voleon Capital Management LP | $1 286 385 | 1 004 988 | 0,19% | Akcje |
| Swiss National Bank | $1 233 920 | 964 000 | 0,19% | Akcje |
Aktywiści i właściciele 5%+ 3 akcje
Inwestorzy, którzy złożyli SEC Schedule 13D — posiadanie beneficjentów powyżej 5% z zamiarem wpływania na emitenta (udziały aktywistów, kampanie zarządu, M&A). Każdy wiersz pokazuje najnowszy znany stan pozycji tego zgłaszającego.
| Zgłaszający | Złożono | Udział | Status | Cel | Zgłoszenie |
|---|---|---|---|---|---|
| 3 lutego 2023 | · | Pierwotne zgłoszenie | · | SEC | |
| Growth Equity Opportunities 17, LLC, New Enterprise Associates 17, L.P., NEA Partners 17, L.P., NEA 17 GP, LLC, Forest Baskett, Ali Behbahani, Carmen Chang, Anthony A. Florence, Jr., Liza Landsman, Mohamad H. Makhzoumi, Joshua Makower, Edward T. Mathers, Scott D. Sandell, Peter W. Sonsini, Paul Walker, Rick Yang | 4 czerwca 2020 | · | Pierwotne zgłoszenie | Inwestycja pasywna | SEC |
| G ERON C ORPORATION ×3 zgłoszenia | 19 sierpnia 2014 | · | Pierwotne zgłoszenie | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Insiderzy spółki 49 insiderów · 28 dyrektorzy generalni · 23 dyrektorzy
| Insider | Rola | Ostatnia aktywność | Posiadane akcje | Kupna 12m | Sprzedaże 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Harout Semerjian | President and CEO | 7 sierpnia 2025 A | · | 0 | 0 | $0 |
| John A Scarlett | Chairman, President and CEO | 27 lutego 2025 P | 12 500 | 0 | 0 | $0 |
| David Greenwood | President, Interim CEO, CFO | 14 czerwca 2011 S | 754 031 | 0 | 0 | $0 |
| Thomas Okarma | President and CEO | 9 lipca 2010 A | 774 560 | 0 | 0 | $0 |
| Michelle Robertson | EVP, CHIEF FINANCIAL OFFICER | 18 lutego 2026 M | 17 645 | 0 | 1 | $-19 119 |
| Olivia Kyusuk Bloom | EVP, Chief Financial Officer | 15 sierpnia 2023 A | 74 588 | 0 | 0 | $0 |
| Graham K Cooper | EVP, Bus Dev & CFO | 17 maja 2012 A | · | 0 | 0 | $0 |
| Alan Colowick | President, Oncology | 2 stycznia 2008 I | 3 028 | 0 | 0 | $0 |
| Andrew J Grethlein | EVP, Chief Operating Officer | 18 lutego 2025 A | 0 | 0 | 0 | $0 |
| Timothy Williams | EVP and Chief Legal Officer | 13 kwietnia 2026 A | · | 0 | 0 | $0 |
| Joseph Eid | EVP, R&D; Chief Medical Office | 17 lutego 2026 A | · | 0 | 0 | $0 |
| Ahmed Elnawawi | EVP, Chief Commercial Officer | 20 października 2025 A | · | 0 | 0 | $0 |
| James Ziegler | EVP, Chief Commercial Officer | 27 lutego 2025 P | 100 000 | 0 | 0 | $0 |
| Scott Alan Samuels | EVP, Chief Legal Officer | 27 lutego 2025 P | 26 682 | 0 | 0 | $0 |
| Faye Feller | EVP, Chief Medical Officer | 10 czerwca 2024 M | 0 | 0 | 0 | $0 |
| Anil Kapur | EVP, Corp Strategy & CCO | 10 czerwca 2024 M | 0 | 0 | 0 | $0 |
| Aleksandra Rizo | EVP, Chief Medical Officer | 16 lutego 2022 A | · | 0 | 0 | $0 |
| Stephen Rosenfield | EVP, Chief Legal Off & Sec | 16 lutego 2022 A | 0 | 0 | 0 | $0 |
| Melissa Kelly Behrs | EVP, Chief Business Officer | 2 lutego 2021 A | 0 | 0 | 0 | $0 |
| Craig C Parker | EVP, Corp Dev & Sci Affairs | 10 lutego 2014 A | · | 0 | 0 | $0 |
| Stephen Michael Kelsey | EVP, R&D, Chief Med Officer | 3 maja 2013 D | 62 272 | 0 | 0 | $0 |
| David Earp | SVP, Corp Transactions | 30 maja 2012 S | 467 406 | 0 | 0 | $0 |
| Katharine E. Spink | SVP Alliance Mgmt & Operations | 14 czerwca 2011 S | 328 561 | 0 | 0 | $0 |
| Jane Lebkowski | SVP, Chief Scientific Officer | 14 czerwca 2011 S | 568 154 | 0 | 0 | $0 |
| Melanie I Nallicheri | SVP Corp Dev | 20 maja 2011 A | 195 000 | 0 | 0 | $0 |
| Fabio M Benedetti | SVP, Chief Med Off, Oncology | 29 maja 2009 A | 80 560 | 0 | 0 | $0 |
| Calvin Harley | VP, CSO Telomerase Tech | 29 maja 2009 A | 134 036 | 0 | 0 | $0 |
| William Stempel | VP and General Counsel | 27 maja 2004 A | 6 521 | 0 | 0 | $0 |
| Robert J. Spiegel | Dyrektor | 30 września 2026 A | 212 161 | 0 | 0 | $0 |
| John F Mcdonald | Dyrektor | 20 maja 2026 A | · | 0 | 0 | $0 |
| Elizabeth G. O'Farrell | Dyrektor | 20 maja 2026 A | 26 220 | 0 | 0 | $0 |
| Dawn Carter Bir | Dyrektor | 20 maja 2026 A | · | 0 | 0 | $0 |
| Susan Molineaux | Dyrektor | 20 maja 2026 A | 130 527 | 0 | 0 | $0 |
| Constantine Chinoporos | Dyrektor | 25 marca 2026 A | · | 0 | 0 | $0 |
| Patricia S Andrews | Dyrektor | 25 marca 2026 A | · | 0 | 0 | $0 |
| Gaurav Aggarwal | Dyrektor | 21 maja 2025 A | 1 970 | 0 | 0 | $0 |
| Bryan V Lawlis | Dyrektor | 21 maja 2025 A | 13 300 | 0 | 0 | $0 |
| Karin Eastham | Dyrektor | 13 stycznia 2023 M | 109 047 | 0 | 0 | $0 |
| Daniel Bradbury | Dyrektor | 29 marca 2019 A | 51 323 | 0 | 0 | $0 |
| Hoyoung Huh | Dyrektor | 15 maja 2018 A | 154 301 | 0 | 0 | $0 |
| Thomas Hofstaetter | Dyrektor | 18 marca 2015 M | 26 564 | 0 | 0 | $0 |
| Thomas Kiley | Dyrektor | 22 maja 2013 D | 171 911 | 0 | 0 | $0 |
| Edward V Fritzky | Dyrektor | 22 maja 2013 D | 186 511 | 0 | 0 | $0 |
| Alexander E Barkas | Dyrektor | 20 maja 2011 A | 353 122 | 0 | 0 | $0 |
| Charles J Homcy | Dyrektor | 11 maja 2011 A | 62 751 | 0 | 0 | $0 |
| ZENNER PATRICK J | Dyrektor | 19 maja 2010 A | 73 710 | 0 | 0 | $0 |
| John Peter Walker | Dyrektor | 30 stycznia 2009 M | 39 119 | 0 | 0 | $0 |
| Robert B Stein | Dyrektor | 23 września 2003 M | 0 | 0 | 0 | $0 |
| MERIX BIOSCIENCE INC | Posiadacz 10% | 16 sierpnia 2004 S | 4 541 100 | 0 | 0 | $0 |
Insiderzy z zgłoszeń SEC Form 3/4/5; netto = tylko otwarty rynek P/S
Posiadanie ETF-ów Posiadane przez 24 fundusze ETF
Waga odzwierciedla wyłącznie bezpośrednie udziały kapitałowe (N-PORT); fundusze oparte na dźwigni lub instrumentach pochodnych mogą posiadać dodatkowe ekspozycje na swapy, które nie są pokazane.
| Fundusz | Waga | Jednostki | Na dzień | Źródło |
|---|---|---|---|---|
| BBP · ETFis Series Trust I | 1,54% | 1 180 129 NS | 31 lipca 2026 | N-PORT |
| QQQS · Invesco Exchange-Traded Fund Trust … | 0,43% | 80 446 SH | 1 października 2026 | Dziennie |
| LABU · Direxion Shares ETF Trust | 0,19% | 741 331 NS | 31 lipca 2026 | N-PORT |
| ESSC · Strategy Shares | 0,13% | 35 108 NS | 31 lipca 2026 | N-PORT |
| IBB · iShares Trust | 0,06% | 4 783 606 SH | 11 września 2026 | Dziennie |
| PWS · Pacer Funds Trust | 0,05% | 10 128 NS | 31 lipca 2026 | N-PORT |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,05% | 45 101 SH | 1 października 2026 | Dziennie |
| IWO · iShares Trust | 0,05% | 5 238 232 SH | 11 września 2026 | Dziennie |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,04% | 599 922 SH | 19 sierpnia 2026 | Dziennie |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,03% | 749 628 SH | 1 października 2026 | Dziennie |
| IWM · iShares Trust | 0,03% | 14 214 009 SH | 11 września 2026 | Dziennie |
| RSSL · Global X Funds | 0,02% | 267 254 NS | 31 lipca 2026 | N-PORT |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,02% | 3 218 859 SH | 19 sierpnia 2026 | Dziennie |
| VXF · VANGUARD INDEX FUNDS | 0,01% | 6 164 114 SH | 19 sierpnia 2026 | Dziennie |
| VHT · VANGUARD WORLD FUND | 0,01% | 1 437 897 SH | 19 sierpnia 2026 | Dziennie |
| FHLC · FIDELITY COVINGTON TRUST | 0,01% | 237 415 NS | 31 lipca 2026 | N-PORT |
| WSML · iShares Trust | 0,01% | 34 308 SH | 10 września 2026 | Dziennie |
| IWV · iShares Trust | 0,00% | 169 800 SH | 10 września 2026 | Dziennie |
| ITOT · iShares Trust | 0,00% | 725 966 SH | 11 września 2026 | Dziennie |
| TILT · FlexShares Trust | 0,00% | 3 634 NS | 31 lipca 2026 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 20 449 234 SH | 19 sierpnia 2026 | Dziennie |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 41 165 SH | 19 sierpnia 2026 | Dziennie |
| ISCB · iShares Trust | · | 21 772 SH | 11 września 2026 | Dziennie |
| ISCV · iShares Trust | · | 107 848 SH | 11 września 2026 | Dziennie |
GERN Konsensus analityków Bycze i niedźwiedzie opinie analityków, 12-miesięczny cel cenowy, potencjał wzrostu
12-miesięczny cel cenowy
4 analityków · 2026-09-28Średnia cel $4.25 +254,2%
Porównanie z porównywalnymi firmami (podbranża GICS) Kluczowe metryki w porównaniu do konkurentów z sektora
Podstawa R/R, ceny według zamknięcia z ostatniego końca roku obrotowego każdej spółki.
| Ticker | Kapitalizacja Rynkowa | P/E | Przychody r/r | Marża Netto | ROE | Marża brutto |
|---|---|---|---|---|---|---|
| GERN | $845M | -10.2 | -60.2% | · | -34.4% | · |
| ARDX | $1.42B | -22.4 | 22.1% | -15.1% | -40.2% | · |
| ANNX | $750M | -3.7 | · | · | -100.7% | · |
| AVTX | $336M | -3.1 | -86.6% | -132642.4% | -83.4% | · |
| CADL | $310M | -7.8 | · | · | -53.7% | · |
| DSGN | $567M | -7.7 | · | · | -32.8% | · |
| GYRE | $645M | 353.0 | 10.2% | 8.5% | 11.7% | · |
| FDMT | $432M | -3.1 | 230194.6% | -164.4% | -30.2% | · |
| ACHV | · | -4.0 | · | · | · | · |
| SLDB | $445M | -2.8 | · | · | -79.5% | · |
Najnowsze wiadomości Najnowsze nagłówki wspominające o tej firmie
Moje wskaźniki Twoja osobista lista obserwowanych — wybrane wiersze z Pełnych Fundamentów
Wybierz wskaźniki, które są dla Ciebie ważne — kliknij + obok dowolnego wiersza w sekcji Pełne dane fundamentalne powyżej.
Twój wybór został zapisany i będzie Ci towarzyszył we wszystkich tickerach.